Metapristone (RU486-derivative) inhibits endometrial cancer cell progress through regulating miR-492/Klf5/Nrf1 axis
Abstract Background Endometrial cancer is an invasive gynecological cancer prevalent in the world. The pathogenesis of endometrial cancer is related to multiple levels of regulation, referring to oestrogen, tumor-suppressor gene (e.g. PTEN) or microRNAs (e.g. miR-23a and miR-29b). Metapristone is a...
Main Authors: | Yue Chang, Min Hao, Ru Jia, Yihui Zhao, Yixuan Cai, Yun Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-01-01
|
Series: | Cancer Cell International |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12935-020-01682-1 |
Similar Items
-
Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
by: Ning Zheng, et al.
Published: (2019-05-01) -
LINC00565 Enhances Proliferative Ability in Endometrial Carcinoma by Downregulating KLF9 [Retraction]
by: Yin X, et al.
Published: (2023-05-01) -
RU486 Metabolite Inhibits CCN1/Cyr61 Secretion by MDA-MB-231-Endothelial Adhesion
by: Suhong Yu, et al.
Published: (2019-11-01) -
KLF2 transcription suppresses endometrial cancer cell proliferation, invasion, and migration through the inhibition of NPM1
by: Xiyun Cheng, et al.
Published: (2023-12-01) -
GNA14 stimulation of KLF7 promotes malignant growth of endometrial cancer through upregulation of HAS2
by: Jing Wang, et al.
Published: (2021-04-01)